Literature DB >> 8764668

Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study.

V S Mattay1, K F Berman, J L Ostrem, G Esposito, J D Van Horn, L B Bigelow, D R Weinberger.   

Abstract

Previous studies in animals and humans suggest that monoamines enhance behavior-evoked neural activity relative to nonspecific background activity (i.e., increase signal-to-noise ratio). We studied the effects of dextroamphetamine, an indirect monoaminergic agonist, on cognitively evoked neural activity in eight healthy subjects using positron-emission tomography and the O15 water intravenous bolus method to measure regional cerebral blood flow (rCBF). Dextroamphetamine (0.25 mg/kg) or placebo was administered in a double-blind, counterbalanced design 2 hr before the rCBF study in sessions separated by 1-2 weeks. rCBF was measured while subjects performed four different tasks: two abstract reasoning tasks--the Wisconsin Card Sorting Task (WCST), a neuropsychological test linked to a cortical network involving dorsolateral prefrontal cortex and other association cortices, and Ravens Progressive Matrices (RPM), a nonverbal intelligence test linked to posterior cortical systems--and two corresponding sensorimotor control tasks. There were no significant drug or task effects on pCO2 or on global blood flow. However, the effect of dextroamphetamine (i.e., dextroamphetamine vs placebo) on task-dependent rCBF activation (i.e., task - control task) showed double dissociations with respect to task and region in the very brain areas that most distinctly differentiate the tasks. In the superior portion of the left inferior frontal gyrus, dextroamphetamine increased rCBF during WCST but decreased it during RPM (ANOVA F (1,7) = 16.72, p < 0.0046). In right hippocampus, blood flow decreased during WCST but increased during RPM (ANOVA F(1,7) = 18.7, p < 0.0035). These findings illustrate that dextroamphetamine tends to "focus" neural activity, to highlight the neural network that is specific for a particular cognitive task. This capacity of dextroamphetamine to induce cognitively specific signal augmentation may provide a neurobiological explanation for improved cognitive efficiency with dextroamphetamine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764668      PMCID: PMC6579012     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

1.  Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects.

Authors:  B Angrist; J Corwin; B Bartlik; T Cooper
Journal:  Biol Psychiatry       Date:  1987-11       Impact factor: 13.382

2.  Effects of d-amphetamine and prefrontal cortical cooling on delayed matching-to-sample behavior.

Authors:  R H Bauer; J M Fuster
Journal:  Pharmacol Biochem Behav       Date:  1978-03       Impact factor: 3.533

3.  Activation of the hippocampus and dentate gyrus by working-memory: a 2-deoxyglucose study of behaving rhesus monkeys.

Authors:  H R Friedman; P S Goldman-Rakic
Journal:  J Neurosci       Date:  1988-12       Impact factor: 6.167

4.  Effects of d- and l-amphetamine on local cerebral glucose utilization in the conscious rat.

Authors:  L R Wechsler; H E Savaki; L Sokoloff
Journal:  J Neurochem       Date:  1979-01       Impact factor: 5.372

5.  Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys.

Authors:  B M Li; Z T Mei
Journal:  Behav Neural Biol       Date:  1994-09

6.  Medial temporal lesions in monkeys impair memory on a variety of tasks sensitive to human amnesia.

Authors:  S Zola-Morgan; L R Squire
Journal:  Behav Neurosci       Date:  1985-02       Impact factor: 1.912

7.  Localization of function within the dorsolateral prefrontal cortex of the rhesus monkey.

Authors:  P S Goldman; H E Rosvold
Journal:  Exp Neurol       Date:  1970-05       Impact factor: 5.330

8.  Methcathinone: a new and potent amphetamine-like agent.

Authors:  R A Glennon; M Yousif; N Naiman; P Kalix
Journal:  Pharmacol Biochem Behav       Date:  1987-03       Impact factor: 3.533

9.  Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder. A regional cerebral blood flow study.

Authors:  P Rubin; S Holm; L Friberg; P Videbech; H S Andersen; B B Bendsen; N Strømsø; J K Larsen; N A Lassen; R Hemmingsen
Journal:  Arch Gen Psychiatry       Date:  1991-11

10.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism.

Authors:  D R Weinberger; K F Berman; B P Illowsky
Journal:  Arch Gen Psychiatry       Date:  1988-07
View more
  26 in total

Review 1.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

2.  Amphetamine Exerts Dose-Dependent Changes in Prefrontal Cortex Attractor Dynamics during Working Memory.

Authors:  Christopher C Lapish; Emili Balaguer-Ballester; Jeremy K Seamans; Anthony G Phillips; Daniel Durstewitz
Journal:  J Neurosci       Date:  2015-07-15       Impact factor: 6.167

3.  Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI.

Authors:  D Y Kimberg; G K Aguirre; J Lease; M D'Esposito
Journal:  Hum Brain Mapp       Date:  2001-04       Impact factor: 5.038

Review 4.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study.

Authors:  C J Vaidya; G Austin; G Kirkorian; H W Ridlehuber; J E Desmond; G H Glover; J D Gabrieli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

6.  Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex.

Authors:  C C Lapish; S Ahn; L M Evangelista; K So; J K Seamans; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  2008-10-15       Impact factor: 4.530

Review 7.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

Review 8.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 9.  Pharmacological manipulation of human working memory.

Authors:  Deanna M Barch
Journal:  Psychopharmacology (Berl)       Date:  2004-01-30       Impact factor: 4.530

Review 10.  Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.

Authors:  José A Apud; Daniel R Weinberger
Journal:  NeuroRx       Date:  2006-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.